Department of Gynaecologic Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; National Advisory Unit on Late Effects After Cancer Treatment, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
National Advisory Unit on Late Effects After Cancer Treatment, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
Gynecol Oncol. 2017 Sep;146(3):630-635. doi: 10.1016/j.ygyno.2017.05.028. Epub 2017 May 25.
Chronic fatigue after treatment is a common adverse event in cancer patients, but there are few studies in long-term survivors of cervical cancer. The aim of this investigation was to explore the prevalence of chronic fatigue and its association with various clinical and treatment-related factors in a population-based cohort of Norwegian cervical cancer survivors treated by any modality.
All patients, treated for cervical cancer from 2000 through 2007 in the Health Region of South-Eastern Norway, cancer-free, alive and aged ≤75years by the end 2013 (n=822) received a questionnaire covering chronic fatigue and other clinical variables.
461 of 822 survivors (56%) completed the questionnaire and 382 entered the analyses. Chronic fatigue was reported by 23% (95% confidence interval 19%-27%) with a median age of 52years (range 32-75) at survey, 11years (range 7-15) after diagnosis. Among survivors treated by minimal invasive- or radical surgery, 19% had chronic fatigue, while the prevalence was 28% in those treated with radiation and concomitant chemotherapy (chemoradiation). The chronic fatigue group reported significantly more cardiovascular disease, obesity, less physical activity, more treatment-related symptom experience, more menopausal symptoms, higher levels of anxiety and depressive symptoms, and poorer quality of life than the non-fatigued group. In multivariate analysis only increased level of depression and poorer global quality of life were significantly associated with chronic fatigue.
Chronic fatigue was reported by 23% of long-term survivors after cervical cancer at a mean of 11years after treatment. Some of the associated factors are amenable to prevention and/or treatment and should be subjects of attention at follow-up.
治疗后慢性疲劳是癌症患者的常见不良反应,但在宫颈癌长期幸存者中研究较少。本研究旨在探索在接受任何治疗方式的挪威宫颈癌幸存者中,基于人群的队列中慢性疲劳的发生率及其与各种临床和治疗相关因素的关系。
所有于 2000 年至 2007 年在挪威东南部卫生区接受宫颈癌治疗、无癌症、生存且截止 2013 年底年龄≤75 岁的患者(n=822)均收到一份涵盖慢性疲劳和其他临床变量的问卷。
822 名幸存者中有 461 名(56%)完成了问卷,382 名进入分析。在调查时,23%(95%置信区间 19%-27%)的人报告患有慢性疲劳,中位年龄为 52 岁(范围 32-75),诊断后 11 年(范围 7-15)。接受微创或根治性手术治疗的幸存者中,19%患有慢性疲劳,而接受放疗和同期化疗(放化疗)的幸存者中,其患病率为 28%。慢性疲劳组报告心血管疾病、肥胖、体力活动较少、更多的治疗相关症状、更多的更年期症状、更高水平的焦虑和抑郁症状以及较差的生活质量显著高于非疲劳组。多变量分析仅显示抑郁程度增加和整体生活质量较差与慢性疲劳显著相关。
在治疗后 11 年的宫颈癌长期幸存者中,有 23%报告患有慢性疲劳。一些相关因素是可以预防和/或治疗的,应该在随访中引起关注。